Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

830
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
830
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

974
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
974
Neural Regulation01:37

Neural Regulation

43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Frontiers in neurology·2026
Same author

Streamlining Alzheimer's disease diagnosis: real-world validation of two-cut-off diagnostic models based on plasma p-tau/Aβ42 ratios.

Journal of neurology·2026
Same author

Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Frontiers in neurology·2026
Same author

Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.

Neurology·2026
Same author

Physical exercise modulates T cell activity and mitigates synaptic dysfunction in multiple sclerosis through vagus nerve engagement.

Brain, behavior, and immunity·2026
Same journal

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease.

Cannabis and cannabinoid research·2026
Same journal

Doctor-Recommended Cannabis Use in the Era of Legalization: Trends from California (2019-2024).

Cannabis and cannabinoid research·2026
Same journal

Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study.

Cannabis and cannabinoid research·2026
Same journal

From Plant to Extract: Different Factors in the Extraction of <i>Cannabis sativa</i> L. Inflorescences.

Cannabis and cannabinoid research·2026
Same journal

Longitudinal Analysis of Cannabinoid Type 1 Receptor in HIV-1 Tat Transgenic Mice Using PET Imaging and Western Blot Analysis.

Cannabis and cannabinoid research·2026
Same journal

<b>Quantification of 14 Major and Minor Cannabinoids with Absorbance</b>-<b>Transmittance Excitation</b>-<b>Emission Matrix Spectroscopy and Machine Learning</b>.

Cannabis and cannabinoid research·2026
See all related articles

Related Experiment Video

Updated: Feb 23, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

27.0K

Cannabinoids in Parkinson's Disease.

Mario Stampanoni Bassi1,2, Andrea Sancesario1, Roberta Morace1

  • 1Neurology and Neurorehabilitation Units, IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy.

Cannabis and Cannabinoid Research
|September 2, 2017
PubMed
Summary
This summary is machine-generated.

Modulating the endocannabinoid system shows promise for Parkinson's disease motor symptoms. However, clinical evidence remains inconclusive, requiring further research for effective cannabinoid therapies.

Keywords:
Parkinson's diseasebasal gangliacannabinoidsdopaminelevodopa-induced dyskinesia

Related Experiment Videos

Last Updated: Feb 23, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

27.0K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • The endocannabinoid system regulates physiological processes and is implicated in movement disorders like Parkinson's disease.
  • Complex interactions exist between cannabinoids, dopamine, and other neurotransmitters within the basal ganglia.

Purpose of the Study:

  • To review the role of the endocannabinoid system in Parkinson's disease.
  • To evaluate the potential of cannabinoid-based therapies for motor and non-motor symptoms.

Main Methods:

  • Analysis of preclinical studies in Parkinson's disease models.
  • Review of experimental data on cannabinoid interactions with various receptor systems.

Main Results:

  • Preclinical studies suggest that modulating the cannabinoid system can alleviate motor symptoms in Parkinson's disease models.
  • Clinical study results for cannabinoid-based treatments in Parkinson's disease are currently controversial and inconclusive.

Conclusions:

  • Further research is needed to clarify the therapeutic potential of cannabinoid-based treatments for Parkinson's disease.
  • Future clinical studies should focus on larger patient cohorts, specific molecular targets, and defined outcome measures.